Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

China Pharma Holdings (CPHI) Revenue: 2009-2025

Historic Revenue for China Pharma Holdings (CPHI) over the last 17 years, with Sep 2025 value amounting to $756,217.

  • China Pharma Holdings' Revenue fell 31.26% to $756,217 in Q3 2025 from the same period last year, while for Sep 2025 it was $4.1 million, marking a year-over-year decrease of 26.92%. This contributed to the annual value of $4.5 million for FY2024, which is 35.41% down from last year.
  • China Pharma Holdings' Revenue amounted to $756,217 in Q3 2025, which was down 26.28% from $1.0 million recorded in Q2 2025.
  • Over the past 5 years, China Pharma Holdings' Revenue peaked at $2.9 million during Q4 2022, and registered a low of $756,217 during Q3 2025.
  • For the 3-year period, China Pharma Holdings' Revenue averaged around $1.3 million, with its median value being $1.1 million (2024).
  • In the last 5 years, China Pharma Holdings' Revenue surged by 33.70% in 2021 and then tumbled by 47.25% in 2024.
  • China Pharma Holdings' Revenue (Quarterly) stood at $2.9 million in 2021, then grew by 1.09% to $2.9 million in 2022, then decreased by 26.41% to $2.1 million in 2023, then plummeted by 47.25% to $1.1 million in 2024, then plummeted by 31.26% to $756,217 in 2025.
  • Its Revenue was $756,217 in Q3 2025, compared to $1.0 million in Q2 2025 and $1.1 million in Q1 2025.